🔎 Trials Near Me

Почетна › Akutna bifentipska leukemija › Тексас › Houston

Kliničke studije za Akutna bifentipska leukemija u gradu Houston, TX

11 studija za Akutna bifentipska leukemija traži učesnike na lokacijama u gradu Houston i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст од 18 до 65 · Оба пола · Ажурирано 12. 11. 2026. · NCT02115295

Personalized NK Cell Therapy in CBT

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст од 15 до 80 · Оба пола · Ажурирано 2. 11. 2026. · NCT02727803

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Тражи се учесникФаза 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
365 Days · Оба пола · Ажурирано 27. 10. 2026. · NCT06317662

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Тражи се учесникФаза 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Узраст од 13 до 90 · Оба пола · Ажурирано 26. 10. 2026. · NCT06533579

A Study of Revumenib and Mezigdomide in People With Leukemia

Тражи се учесникФаза 1/2
  • MD Anderson Cancer Center (Data Collection Only), Houston
Узраст 12 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07356154

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Тражи се учесникФаза 1
  • University of Texas MD Anderson Cancer Center, Houston
Узраст од 12 до 78 · Оба пола · Ажурирано 29. 9. 2026. · NCT03802695

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Тражи се учесникФаза 2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03683433

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Тражи се учесникФаза 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
365 Days – 25 Years · Оба пола · Ажурирано 25. 8. 2026. · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Тражи се учесникФаза 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Тражи се учесникФаза 1/2
  • M D Anderson Cancer Center, Houston
Узраст 18 и старији · Оба пола · Ажурирано 12. 6. 2026. · NCT04047641

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Тражи се учесникФаза 1
  • Texas Children's Hospital/Baylor College of Medicine, Houston
Узраст од 1 до 21 · Оба пола · Ажурирано 6. 12. 2024. · NCT05476770

Studije za Akutna bifentipska leukemija u drugim gradovima

Ostale studije u gradu Houston

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.